Oh Tak Kyu, Song In-Ae, Jeon Young-Tae
Department of Anesthesiology and Pain Medicine, Seoul National University Bundang Hospital, Gumi-ro 173 Beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do 13620, Korea.
Department of Anesthesiology and Pain Medicine, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul 03080, Korea.
J Pers Med. 2021 Feb 10;11(2):116. doi: 10.3390/jpm11020116.
We aimed to investigate whether statin therapy is associated with the incidence of coronavirus disease 2019 (COVID-19) among the South Korean population. In addition, we examined whether statin therapy affects hospital mortality among COVID-19 patients. The National Health Insurance Service (NHIS)-COVID-19 database in South Korea was used for data extraction for this population-based cohort study. A total of 122,040 adult individuals, with 22,633 (18.5%) in the statin therapy group and 101,697 (91.5%) in the control group, were included in the analysis. Among them, 7780 (6.4%) individuals were diagnosed with COVID-19 and hospital mortality occurred in 251 (3.2%) COVID-19 cases. After propensity score matching, logistic regression analysis showed that the odds of developing COVID-19 were 35% lower in the statin therapy group than in the control group (odds ratio: 0.65, 95% confidence interval: 0.60 to 0.71; < 0.001). Regarding hospital mortality among COVID-19 patients, the multivariable model indicated that there were no differences between the statin therapy and control groups (odds ratio: 0.74, 95% confidence interval: 0.52 to 1.05; = 0.094). Statin therapy may have potential benefits for the prevention of COVID-19 in South Korea. However, we found that statin therapy does not affect the hospital mortality of patients who are diagnosed with COVID-19.
我们旨在调查在韩国人群中，他汀类药物治疗是否与2019冠状病毒病（COVID-19）的发病率相关。此外，我们还研究了他汀类药物治疗是否会影响COVID-19患者的医院死亡率。本基于人群的队列研究使用了韩国国家健康保险服务（NHIS）-COVID-19数据库进行数据提取。分析共纳入122,040名成年人，其中他汀类药物治疗组有22,633人（18.5%），对照组有101,697人（91.5%）。其中，7780人（6.4%）被诊断为COVID-19，251例（3.2%）COVID-19病例发生了医院死亡。倾向得分匹配后，逻辑回归分析显示，他汀类药物治疗组发生COVID-19的几率比对照组低35%（比值比：0.65，95%置信区间：0.60至0.71；P<0.001）。关于COVID-19患者的医院死亡率，多变量模型表明他汀类药物治疗组和对照组之间没有差异（比值比：0.74，95%置信区间：0.52至1.05；P = 0.094）。他汀类药物治疗可能对韩国预防COVID-19有潜在益处。然而，我们发现他汀类药物治疗不会影响被诊断为COVID-19患者的医院死亡率。
